Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The Biosimilars Market Report Is Available Now!
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • Transition Day for Insulins, Other Products March 24, 2020
  • A Conversation With Christine M. Simmon, Executive Director, Biosimilars Council and Senior VP, Policy and Strategic Alliances, Association for Accessible Medicines March 24, 2020
  • Partners Teva and Celltrion Announce Launch of Herzuma March 18, 2020
  • A Conversation With Leah Christl, PhD, Executive Director, Global Regulatory and R&D Policy at Amgen March 13, 2020
  • The Plan That Convinced Canada to Switch to Biosimilars March 12, 2020
  • The FDA/FTC Workshop: Beginning to Address Misleading Biosimilar Information March 10, 2020
  • Mylan Reports FDA Submission for Bevacizumab Biosimilar March 6, 2020
  • 26/15/9: Biosimilars at the Crossroads March 5, 2020
  • Taking the Long View on Biosimilar Markets February 14, 2020
  • Merck to Spin Off Company That Will Include Its Biosimilar Marketing in 2021 February 7, 2020

Recent Comments

Steve Miller on Partners Teva and Celltrion An…
FiercePharmaPolitics… on How Did Kaiser Permanente Reac…
FiercePharmaPolitics… on How Did Kaiser Permanente Reac…
steven miller on Partners Teva/Celltrion Seek t…
Momenta Drops Out of… on A Momentous Decision: Momenta…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • Sandoz Sets Ziextenzo Price 37% Below WAC for Reference Neulasta
  • A Profile of a Lesser-Known Player in the Biosimilar Space: Polpharma Biologics
  • Can Biosimilars Be Protected By Patent?
  • Ruxience
  • Apotex/Apobiologix: Success in Canada, but Are They Shelving Biosimilars in the US?
  • Zirabev
  • Pfizer Launches Ruxience, Announces Pricing for Upcoming Trazimera
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2015-2020 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.